title: Congenital toxoplasmosis from a mother with type 2 diabetes mellitus: a case report.
abstract: A 33-year-old woman with type 2 diabetes mellitus (DM) was suspected of being primarily infected with Toxoplasma gondii at 12 weeks of gestation (GW). Although acetylspiramycin was started at 17 GW, the T. gondii DNA gene was detected in the amniotic fluid at 18 GW. Chemotherapy was changed to pyrimethamine plus sulfadiazine from 20 GW, but was changed back to acetylspiramycin after 2 weeks because of vomiting. Acetylspiramycin was continued until her delivery. DM was controlled well during the pregnancy. An asymptomatic male baby was born by cesarean section at 37 GW, and was treated with acetylspiramycin for 4 weeks because the polymerase chain reaction results of umbilical cord blood were positive. He has developed normally until the present, that is, 6 months of age. Herein, we describe a case report in which symptomatic congenital toxoplasmosis was avoided in a pregnant woman with an immunosuppressive risk due to prompt chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Nakatsu Municipal Hospital, Oita, Japan.
authors.forename: Shimpei
authors.initials: S
authors.lastname: Sato
authors.forename: Masakazu
authors.initials: M
authors.lastname: Nishida
authors.forename: Kaei
authors.initials: K
authors.lastname: Nasu
authors.forename: Hisashi
authors.initials: H
authors.lastname: Narahara
authors.forename: Kazumi
authors.initials: K
authors.lastname: Norose
authors.forename: Fumie
authors.initials: F
authors.lastname: Aosai
mesh_terms: D000328:Adult; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D016867:Immunocompromised Host / Q000187:drug effects*; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D011262:Pregnancy Trimester, Second; D011254:Pregnancy in Diabetics / Q000188:drug therapy / Q000276:immunology*; D014122:Toxoplasma / Q000187:drug effects / Q000254:growth & development; D014123:Toxoplasmosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D007004:Hypoglycemic Agents
keywords: magnetic resonance imaging; obesity; pregnancy; second trimester; visceral adiposity